Tenax Therapeutics, Inc. (NASDAQ:TENX) Sees Significant Growth in Short Interest

Tenax Therapeutics, Inc. (NASDAQ:TENX) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 419,500 shares, an increase of 93.1% from the January 31st total of 217,200 shares. Approximately 14.1% of the company’s stock are short sold. Based on an average daily trading volume, of 50,200 shares, the days-to-cover ratio is presently 8.4 days.

Tenax Therapeutics Stock Performance

TENX stock traded down $0.05 during trading on Friday, hitting $5.96. 6,182 shares of the company’s stock traded hands, compared to its average volume of 39,092. The business has a fifty day simple moving average of $6.42 and a two-hundred day simple moving average of $5.09. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89.

Hedge Funds Weigh In On Tenax Therapeutics

Several institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP purchased a new position in Tenax Therapeutics during the fourth quarter valued at approximately $84,000. Millennium Management LLC purchased a new position in Tenax Therapeutics in the fourth quarter worth $166,000. Janus Henderson Group PLC purchased a new position in Tenax Therapeutics in the fourth quarter worth $1,026,000. Geode Capital Management LLC grew its holdings in Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in Tenax Therapeutics in the third quarter worth $101,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.